| 1.68 0.03 (1.82%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.08  |
1-year : | 2.39 |
| Resists | First : | 1.78 |
Second : | 2.04 |
| Pivot price | 1.67 |
|||
| Supports | First : | 1.36 |
Second : | 1.13 |
| MAs | MA(5) : | 1.63  |
MA(20) : | 1.71 |
| MA(100) : | 1.66 |
MA(250) : | 1.2 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.9 |
D(3) : | 34.7 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 2.85 | Low : | 0.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CNTB ] has closed above bottom band by 49.9%. Bollinger Bands are 40.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.55 - 1.56 | 1.56 - 1.57 |
| Close: | 1.63 - 1.65 | 1.65 - 1.67 |
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - The Herald-Times
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - Zanesville Times Recorder
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - The News Leader | Staunton, VA
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - The Sheboygan Press
Sun, 02 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - Cape Cod Times
Sun, 02 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - The Palm Beach Post
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 1.434e+007 (%) |
| Held by Institutions | 40.5 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.906e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -27 % |
| Return on Assets (ttm) | 966.6 % |
| Return on Equity (ttm) | -30.6 % |
| Qtrly Rev. Growth | 1.97e+006 % |
| Gross Profit (p.s.) | 0.46 |
| Sales Per Share | 0.46 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 3.56 |
| Price to Cash Flow | -0.19 |
| Dividend | 0 |
| Forward Dividend | 64300 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|